Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 21 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/1/1998


1.		Phase II/III Randomized Study of High-Dose vs Moderate-Dose LGD1069 vs Placebo in Advanced non-Small Cell Lung Cancer (Summary Last Modified 08/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				LIGAND-L1069-20 NCI-V96-1050

Last Modified: 5/1/1999


2.		Phase II/III Study of Targretin (LGD1069) Capsules in Patients with Refractory or Recurrent Early Stage T-Cell Lymphomas (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				LIGAND-L1069-23 NCI-V97-1149

Last Modified: 11/1/1998


3.		Phase II/III Evaluation of Targretin Capsules in Patients with Refractory Advanced Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 11/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				LIGAND-L1069-24 NCI-V97-1151

Last Modified: 12/1/1998


4.		Phase III Study of Targretin (LGD1069) Topical Gel in Patients with Refractory or Persistent Early Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				LIGAND-L1069T-25 NCI-V97-1292

Last Modified: 6/2/2005 First Published: 2/1/2002


5.		Phase III Randomized Study of Cisplatin and Vinorelbine With or Without Bexarotene in Patients With Chemotherapy-Naive Advanced or Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Pharmaceutical / Industry				LIGAND-L1069-49

Last Modified: 11/29/2006 First Published: 5/1/2002


6.		Phase III Randomized Study of Carboplatin and Paclitaxel With Bexarotene Versus Carboplatin and Paclitaxel Alone in Patients With Chemotherapy-Naive Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Pharmaceutical / Industry				LIGAND-L1069-48 BMC-C-7093-49, UCLA-0301086

Last Modified: 9/1/1998


7.		Phase I/II Pilot Study of Topical LGD1069 (a Selective Retinoid) for Cutaneous T-Cell Lymphoma (Summary Last Modified 09/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 18				Other				MDA-DM-94098 NCI-V95-0621

Last Modified: 12/1/1998


8.		Phase I/II Multicenter Study of Combination Therapy With LGD1069 Oral Capsules (Targretin) and Interferon Alfa-2b (Intron A) in Patients With Advanced Renal Cell Carcinoma (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				UCLA-HSPC-960630001 LIGAND-L1069-17, LIGAND-UCLA-HSPC-960630001, NCI-V97-1205

Last Modified: 12/1/1998


9.		Phase II Study of Oral LGD1069 plus IFN-A for Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				YALE-HIC-8644 LIGAND-YALE-HIC-8644, NCI-V96-0882

Last Modified: 7/1/1998


10.		Phase II Study of Oral LGD1069 (a Synthetic Retinoid Analogue) for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 07/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				LIGAND-L1069-21 NCI-V96-0973

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute